MondaySep 27, 2021 1:07 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Eyes Commercial Plans to Become B2B Wholesale Supplier of Rare Cannabinoids

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage company based in British Columbia, Canada, is focused on advancing a pipeline of cannabinoid-based pharmaceutical drug candidates. The company is developing a proprietary cannabinoid synthesis manufacturing system known as IntegraSyn(TM), which is designed to advance rare and lesser-known cannabinoid production to commercial levels. A recent article discussing this quotes InMed CEO Eric A. Adams. “The next key milestone is to manufacture our first large-scale batch through a pharma-grade-ready process in the coming months. We will continue to optimize the process and scale up the IntegraSyn process into larger vessels,” Adams said in a recent…

Continue Reading

MondaySep 27, 2021 12:52 pm

QualityStocksNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Completes First Step in European Expansion Plan

Flora Growth Corp. (NASDAQ: FLGC) recently closed a €2 million investment in Hoshi International Inc., a fully integrated cannabis company, and uniquely positioned to become the leading provider of cannabis and derivative products for the budding European market. With the investment, Flora is set to capitalize on Hoshi’s strong European presence as well as leverage its technical know-how and understanding of its European market to not only expand its reach but also obtain its European Union Good Manufacturing Practices (“EU-GMP”) certification. A recent article reads, “Flora hopes to capitalize on Hoshi’s understanding of and presence within the European market to…

Continue Reading

MondaySep 27, 2021 11:56 am

QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Working to Bring Psychedelic Treatments Closer to the People

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) is contributing to the ongoing conversation around the use of psychedelics in the field of medicine, thereby stamping its position as a leader in the psychedelic renaissance. This follows efforts by the scientific community in the 21st century to prove the potential of psychedelics to rewire or repair circuits in the brain. Specifically, Tryp is bringing light to psilocybin usage in diseases with high unmet needs, including chronic pain, through its Psilocybin-For Neuropsychiatric Disorders (TM) (“PFN”) program. “With its three strategic initiatives — develop, protect and monetize — Tryp remains committed to utilizing FDA’s…

Continue Reading

MondaySep 27, 2021 11:46 am

QualityStocksNewsBreaks – SRAX Inc. (NASDAQ: SRAX) Spotlights Companies in Burgeoning EdTech Space at Inaugural Conference

SRAX (NASDAQ: SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its software-as-a-service (“SaaS”) platform, brought together some of the stars within the education technology (“EdTech”) market in the first-ever Sequire EdTech Conference. The event featured prominent virtual work and remote learning companies and touched multiple value points for SRAX by featuring a burgeoning industry as a key opinion leader, showing off its platform to potential clients and investors and spotlighting public companies in the EdTech space. With the fall season expected to again be challenging for schools following the prominence of the…

Continue Reading

FridaySep 24, 2021 2:08 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Enhancing Performance of Antiviral Drugs, CBD

Lexaria Bioscience Corp. (NASDAQ: LEXX) is making significant progress in advancing its patented DehydraTECH(TM) drug delivery technology. Lexaria recently reviewed its successful 2021 antiviral drug program. “The company has progressed significantly in evidencing that DehydraTECH can sufficiently enhance the usable fraction of known antiviral drugs that reach the bloodstream to safely and more effectively do what they are designed to accomplish,” reads a recent article. In addition to the antiviral program, Lexaria is also focused on another applied R&D program — hypertension. On July 29, it released partial results from a human clinical study, HYPER-H21-1, evaluating DehydraTECH-processed cannabidiol (“CBD”) for…

Continue Reading

FridaySep 24, 2021 1:54 pm

QualityStocksNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Continuing Momentum to Grow Sales, Revenue

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) is a pioneer in cannabis and hemp-derived product lines, strategically positioning itself to be among the top three multistate operators of these products within the American market. In late July of this year, the company released its Q1 2021 financial results in what Brand Rogers, RWB Chairman and CEO, described as “another great quarter for the company.” A recent article reads, “When making the announcement, Mr. Rogers also noted that the company would be building on the momentum from Q1, given how much traction it had received for its brand. More…

Continue Reading

FridaySep 24, 2021 1:39 pm

QualityStocksNewsBreaks – AnPac Bio-Medical Science Co. Ltd.’s (NASDAQ: ANPC) CDA Technology Detects Risk of Over 25 Different Cancer Types

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, is a recognized innovator and leader in the field of early cancer screening and detection. Its core product and proven revenue generator, the pioneering Cancer Differentiation Analysis (“CDA”) platform, offers novel capabilities by looking for signals to help it assess the risk of cancer occurring before a tumor has developed. This approach is unlike the blood sample-based cancer screenings, which generally target protein-based biomarkers, genomic signals, such as circulating tumor DNA (“ct-DNA”), circulating in the bloodstream to determine if a cancer exists and is spreading.…

Continue Reading

FridaySep 24, 2021 1:28 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Garners Attention as ‘Emerging Leader in the Psychedelic Therapeutics Space’

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its Q1 2021 operational and financial report for the period ended June 30, 2021. The biotech company hit several milestones, including becoming the first psychedelic company to list on the NYSE American LLC stock exchange and raising more than CA$120 million. In addition, Cybin has started the next phase of its digital therapeutics platform, signed an exclusive R&D collaboration agreement with TMS NeuroHealth Centers Inc to establish Mental Health Centers of Excellence, as well as commenced scaling up its…

Continue Reading

ThursdaySep 23, 2021 2:23 pm

QualityStocksNewsBreaks – Brain Scientific Inc.’s (BRSF) Proprietary Brain Diagnostics Devices Positioned to Profoundly Shift EEG Market

Brain Scientific (OTCQB: BRSF), a commercial-stage medical device and software company focused on neurology, is leveraging artificial intelligence (“AI”) and machine learning (“ML”) to improve diagnostic capability using a database of biomarkers that collect data on both normal and abnormal brain information. Brain Scientific’s use of AI and ML is part of its overall strategy to penetrate the rapidly growing electroencephalogram (“EEG”) market. The strategy includes developing its patented FDA-cleared NeuroCap(TM) and NeuroEEG(TM) devices. NeuroCap is a disposable pre-gelled EEG headset with 22 electrodes and 19 active EEG channels that can be used to record EEGs in nearly any setting.…

Continue Reading

ThursdaySep 23, 2021 2:03 pm

QualityStocksNewsBreaks – FingerMotion Inc. (FNGR) Committed to Increasing Market Reach, Product Line, Quality of Offerings

FingerMotion (OTCQX: FNGR) has always endeavored to deliver the next generation of data-driven technology solutions that cut across its current product line and service offerings. Even so, the company, which currently provides solutions to the Chinese market, is seeking expansion. “Going forward, it seeks to expand into other regions and further introduce other innovative offerings, mainly in collaboration with other tech companies in specific industries. So far, associations with Happy Life Insurance and Xunlian Tanxia Technology show FNGR’s commitment to this path and highlight its future,” reads a recent article. “This company is committed to growing its user base organically,…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered